Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)

This study is an open-label, single-arm, dose-escalation trial primarily designed to evaluate the safety and efficacy of a universal CAR-T cell therapy targeting CD19 in the treatment of patients with RJDM. Additionally, the study aims to characterize its pharmacokinetic and pharmacodynamic properties, explore its role in immune system reconstitution, and assess long-term survival benefits.

NCT Number	NCT06686524
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	Dermatomyositis, Juvenile, Dermatomyositis
Enrollment	18 participants
Start Date	2024-11-11
Primary Completion	2026-11-10 (estimated)
Study Completion	2027-11-10 (estimated)
Updated on ClinicalTrials.gov	2024-11-13